VC Versant Ventures is unveiling Dayra Therapeutics, a new biotech working on oral macrocyclic peptide drugs—a mission that has already reeled in a partnership with Biogen. | VC Versant Ventures is ...

Johnson & Johnson’s attempt to develop a $5 billion-a-year Alzheimer’s disease drug has been rocked by a phase 2 flop. | Johnson & Johnson’s attempt to develop a $5 billion-a-year Alzheimer’s disease ...

Solventum estimates that Acera will likely post about $90 million in sales for 2025. The deal is expected to be "slightly dilutive" to adjusted earnings per share in 2026 and accretive to adjusted ...

Bayer’s oral FXIa inhibitor asundexian has significantly reduced the risk of stroke in a phase 3 trial, giving a boost to a potentially blockbuster mechanism that has suffered setbacks over the past ...

The November storm clouds may have parted above the Jefferies Global Healthcare Conference in London last week, but market ...

The survey was disseminated among biopharma CEOs and regulatory affairs leaders and focused on recent experiences with the ...

The CDC is instructing scientists to end all research involving monkeys by the end of the year, in a move that will ...

The FDA says it is hiring more than 1,000 new employees and rolling out a pilot communication program in efforts to speed up ...

Roche has claimed the exclusive international rights to Freenome’s multiomic cancer screening approaches, toward the goal of ...

The Fierce team will be out of office next Friday for the Thanksgiving holiday. The next edition of Chutes & Ladders will ...

Nurix Therapeutics is trimming its workforce not long after launching a pivotal phase 2 trial for its lead cancer asset. | ...

Contineum Therapeutics’ M1 receptor antagonist has failed to move the needle in a phase 2 vision test for patients with a common form of multiple sclerosis. | Contineum Therapeutics’ M1 receptor ...